Salute e Benessere

EssilorLuxottica Completes Acquisition of a Majority Stake in Heidelberg…

EssilorLuxottica Completes Acquisition of a Majority Stake in Heidelberg EngineeringParis, France and Heidelberg, Germany (October 2, 2024 – 7am CEST) – EssilorLuxottica, a global leader in the optical industry, announced it has completed thepreviously announcedtransaction to acquire an 80% stake in Heidelberg Engineering, a Germany-based company specializing in diagnostic solutions, digital surgical technologies and healthcare IT for clinical ophthalmology. The transaction has...
Nasdaq GlobeNewswire
02/10/2024

EssilorLuxottica Completes Acquisition of Supreme® from VF Corporation

EssilorLuxottica Completes Acquisition ofSupreme ® from VF Corporation Paris, France and Denver, Colorado (USA) (October 2, 2024 – 7am CEST)– EssilorLuxottica, a global leader in the optical industry, announced that it has successfully closed thepreviously announcedtransaction to acquire theSupreme ® brand from VF Corporation (NYSE: VFC), a global leader in branded lifestyle apparel, footwear and accessories, for an aggregate base purchase price of $1.5 billion in cash...
Nasdaq GlobeNewswire
02/10/2024

CARBIOS announces half-year 2024 financial results and presents its industrial…

Construction progress of world's first PET enzymatic biorecycling plant in France: in line with production targets in 2026Commercial development: several Letters of Intent signed in view of licensing agreementsConsolidated cash position of €120.7 million on 30 June 2024, plus €23.4 million in term deposits classified as financial assets. In addition, €42.5 million in public funding is expected. Clermont-Ferrand (France), Wednesday 02 October 2024 (6:45am CEST). CARBIOS,...
Nasdaq GlobeNewswire
02/10/2024

PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight

Key Takeaways from the PLK-1 Inhibitors Market Report Key Takeaways from the PLK-1 Inhibitors Market Report Discover which therapies are expected to grab the PLK-1 inhibitors market share @ PLK-1 Inhibitors Market Report PLK-1 Inhibitors Market Dynamics The PLK-1 inhibitors market is a rapidly evolving sector within the oncology pharmaceutical landscape. One of the primary drivers of the PLK-1 inhibitors market is theincreasing prevalence of cancerand thedemand for more...
PR Newswire
01/10/2024

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08.The Company is issuing this...
Nasdaq GlobeNewswire
01/10/2024

IBA - Regulated Information

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)Louvain-la-Neuve, Belgium, October 1st, 2024 06:00 Summary of the notificationIBA (Ion Beam Applications), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification...
Nasdaq GlobeNewswire
01/10/2024

LAPSI HEALTH'S KEIKKU GETS FDA CLASS II CLEARANCE AND LAUNCHES IN THE U.S. WITH…

Lapsi means 'child' in Finnish (As the company has Dutch-Finnish roots), Keikku means 'tool'. Lapsi means 'child' in Finnish (As the company has Dutch-Finnish roots), Keikku means 'tool'. Dr.Diana van Stijn, MD, Chief Medical Officer of Lapsi Health, emphasizes the disruptive potential of Keikku: "Sound has always been key in diagnostics, but with Keikku, we're turning it into actionable data that can revolutionize and empower medical care." Unlike traditional stethoscopes, Keikku...
PR Newswire
01/10/2024

China Neurogenomics Market to Reach $562.1 Million by 2031 - Exclusive Report by…

Download FREE PDF Brochure Of China Neurogenomics Market –https://www.meticulousresearch.com/product/china-neurogenomics-market-6003 Download FREE PDF Brochure Of China Neurogenomics Market – https://www.meticulousresearch.com/product/china-neurogenomics-market-6003 The growth of this market is driven by the declining costs of sequencing, the increasing prevalence of neurological disorders, the growing utilization of advanced sequencing technologies in disease diagnostics &...
PR Newswire
01/10/2024

Sleep Apnea Oral Appliances Market to Hit USD 746.6 Million by 2029 with 9.6%…

Browse in-depth TOC on "Sleep Apnea Oral Appliances Market" Browse in-depth TOC on "Sleep Apnea Oral Appliances Market" 295 - Tables 45 - Figures 287 - Pages The global sleep apnea oral appliances market is bringing new advancements in the mandibular advancement devices. More innovations are being done on the mandibular advancement devices for making it custom fit for the users, custom made devices are made to made to provide durability and comfort. Glidewell (US) launched…
PR Newswire
01/10/2024

Conformal Medical Announces Launch of the GLACE Study with Next-Gen CLAAS®…

Initial patients were treated by the study's co-principal investigators Professor Jens Erik Nielsen-Kudsk, M.D. of Aarhus University Hospital and Professor Ole De Backer, M.D. of Rigshospitalet, Copenhagen University Hospital at their respective institutions in Denmark. Additionally, Shephal Doshi, M.D., from Providence Saint John's Health Center and the Pacific Heart Institute in Santa Monica, California and Principal Investigator of the CONFORM Pivotal Trial was present for the initial cases…
PR Newswire
01/10/2024

PeptiGrowth Inc. is Launching a Novel Synthetic FGF2 Alternative Peptide (FGFR1c…

Traditional growth factors and cytokines used in regenerative medicine and cell therapy manufacturing face several quality issues, including lot-to-lot variability, potential contamination with biological impurities, low stability, and high costs. PeptiGrowth has focused on developing a series of synthetic peptides that address these challenges while maintaining functionality equivalent to conventional growth factors and cytokines. Their peptides are completely chemically synthesized and free…
PR Newswire
01/10/2024

Mölnlycke® Health Care acquires P.G.F. Industry Solutions GmbH, the manufacturer…

"The acquisition of P.G.F. will allow Mölnlycke to expand our Granudacyn business and further develop our growing wound care portfolio. Granudacyn effectively cleanses wounds, which supports healing, ultimately helping to ease the burden of wounds" says Zlatko Rihter, CEO of Mölnlycke Health Care. "The acquisition of P.G.F. will allow Mölnlycke to expand our Granudacyn business and further develop our growing wound care portfolio. Granudacyn effectively cleanses wounds, which…
PR Newswire
01/10/2024

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR…

This first-to-market launch showcases Teva's proven strengths in complex generic formulations andenhancesTeva's strategic goal of sustaining a generic powerhouse . Octreotide acetate for injectable suspension is indicated to treat acromegaly and severe diarrhea for carcinoid syndrome .PARSIPPANY, N.J., Oct.01, 2024(GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the...
Nasdaq GlobeNewswire
01/10/2024

ClariMed Inc. Strengthens Leadership Team with Joe Dobkin as New VP of Services

In his new role as Vice President of Services, Dobkin will spearhead service delivery, optimize processes, and help expand ClariMed's offerings to better serve clients. Known for his thoughtful approach, attention to detail, and calm presence, Dobkin's leadership style aligns well with ClariMed's cultural values. His initial focus will be on learning about ClariMed's people and processes, setting a strong foundation for future growth and optimization. In his new role as Vice President of...
PR Newswire
01/10/2024

Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer…

Collaboration to include the clinical development, regulatory filing, and commercialization in Japan of177 Lu-PSMA-I&T and64 Cu-PSMA-I&TBuilds on long-standing relationship between the two companiesIn Japan around 90,000 new cases of prostate cancer are diagnosed each year PARIS, Oct.01, 2024(GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has entered into a strategic partnership with PDRadiopharma Inc, a wholly-owned subsidiary of...
Nasdaq GlobeNewswire
01/10/2024

RevitaLash® Cosmetics Announces New Milestone of Over $9 Million Committed to…

As part of its ongoing Eternally Pink® pledge, RevitaLash Cosmetics continues its year-round philanthropic mission by donating a portion of proceeds from every product sold to directly fund groundbreaking research and make lifesaving care accessible to more patients. As part of its ongoing Eternally Pink® pledge, RevitaLash Cosmetics continues its year-round philanthropic mission by donating a portion of proceeds from every product sold to directly fund groundbreaking research and make...
PR Newswire
01/10/2024

Auto Depth Digital Wound Measurement Now Available on MolecuLightDX

Standard of care depth measurements, made using a probe and ruler, are often inaccurate with a high degree of variability in measured depths across different clinicians, usually resulting in overestimation. The new MolecuLightDX Auto Depth feature will help to standardize wound measurement across multiple providers. This new feature has been extensively tested and validated to ensure exceptional accuracy and robust reliability within a real clinical environment on real patient wounds…
PR Newswire
01/10/2024

BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day

Provides updates on BioNTech's strategy to scale and deploy AI-capabilities across the immunotherapy pipelineHighlights InstaDeep's new near exascale supercomputer, Kyber, with the aim of enabling BioNTech to compute at scaleUnveils novel AI Bayesian Flow Network (“BFN”) models for protein sequence generationHighlights progress in deploying AI across BioNTech's immunotherapy pipeline, including in immunohistochemistry, DNA/RNA sequencing, proteomics, protein design, and lab...
Nasdaq GlobeNewswire
01/10/2024

Responding to spine surgeons' educational needs, AO Spine rolls out new…

Each course addresses selected, standardized learning objectives, based on the AO Spine Curriculum, ensuring AO Spine quality standards are met for each participant, no matter where they decide to attend the course. Each course addresses selected, standardized learning objectives, based on the AO Spine Curriculum, ensuring AO Spine quality standards are met for each participant, no matter where they decide to attend the course. The new courses offer participants a unique pathway to surgical...
PR Newswire
01/10/2024

Relu Secures FDA 510(k) and CE Marking for Revolutionary Dental Software Relu®…

FDA clearance signifies compliance with U.S. medical device standards, while the CE Mark confirms adherence to EU regulations for product safety and consumer protection. This dual recognition underscores Relu's commitment to excellence in the oral health sector. "We are thrilled to have attained both FDA and CE approval for the Relu® Creator," statedAdriaan Van Gerven, CTO and Co-founder, of Relu. "These significant achievements are a testament to Relu's dedication to creating...
PR Newswire
01/10/2024

AstronauTx appoints Jane Rhodes as Chief Executive Officer and Expands Executive…

A neuroscientist by training, Jane began her career in the field of discovery research and worked on novel therapies for Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), stroke and multiple sclerosis (MS). She has contributed to the development and launch of several marketed products for neurological indications over the span of her career. A neuroscientist by training, Jane began her career in the field of discovery research and worked on novel therapies for...
PR Newswire
01/10/2024

Resolution Therapeutics Announces Upcoming Presentations at the American…

EDINBURGH, Scotland and LONDON, Oct. 1, 2024 Resolution Therapeutics Limited ("Resolution" or "Company"), a clinical-stage biopharmaceutical company focused on unlocking the regenerative potential of macrophage therapy for the treatment of inflammatory and fibrotic diseases, today announces two abstracts have been selected for presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024. The conference will take place in San Diego…
PR Newswire
01/10/2024

Implantica welcomes 23 top anti-reflux surgeons from 17 leading centers in the…

Dr. med. Jörg Zehetner, a leading anti-reflux surgeon from Switzerland with about 150 RefluxStop procedures completed, led this training. He says, "I was honored to lead the RefluxStop training in Spain where I have visited and proctored most of the RefluxStop Surgeons over the past 1.5 years. The atmosphere in this meeting was phenomenal as the Spanish surgeons discussed the promising outcomes of RefluxStop experienced in their own practice. Since RefluxStop does not encircle the food…
PR Newswire
01/10/2024

Neuraxpharm expands operations into the Middle East

Neuraxpharm's move into the Middle East follows the opening of affiliates in Brazil and Mexico in 2023 and adds to the growing list of more than 20 European countries where the Company is now established alongside its global network of distributors. Neuraxpharm's move into theMiddle Eastfollows the opening of affiliates inBrazilandMexicoin 2023 and adds to the growing list of more than 20 European countries where the Company is now established alongside its global network of distributors...
PR Newswire
01/10/2024
Altri  Comunicati